Pulsenmore prices $7.5M private placement with single institutional investor
What's the deal? PulsenmoreDealroom has a profile for this one. Try Dealroom →, an Israeli pioneer in home ultrasound technology, has priced a $7.5 million private placement with a single healthcare-focused institutional investor.
The Ramat Gan-based company, listed on both the Nasdaq and Tel Aviv exchanges, agreed to sell 1,562,500 ordinary shares and accompanying warrants at a combined price of $4.80 each.
The deal is structured at a premium to the Nasdaq minimum price, with closing expected on or about June 26, 2026.
Why now? Chief executive officer Elazar Sonnenschein said the financing supports the company's "next phase of growth" and aims to expand its commercial footprint, particularly in the US.
Pulsenmore plans to use the net proceeds for marketing, commercialisation, and working capital.
What could go wrong? The warrants carry an exercise price of $4.80 and expire in five years, so dilution looms if the investor converts.
The securities are unregistered, and Pulsenmore has agreed to file a resale registration statement with the US Securities and Exchange Commission. Until that clears, the shares can't be freely traded in the US.
A.G.P./Alliance Global Partners acted as sole placement agent.
The signal: Pulsenmore remains an early-stage player betting that at-home ultrasound can deliver convenience and efficiency beyond traditional in-facility imaging, and this raise is squarely aimed at proving that thesis in the US. With a single healthcare-focused institutional investor backing the placement at a premium to the Nasdaq minimum, the company is leaning on conviction capital rather than broad market appetite to fund its commercial push.
Image credit: Pulsenmore
